Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators.

Abstract

Pompe disease is a lysosomal storage disease (LSD) caused by a deficiency in the lysosomal enzyme acid alpha-glucosidase. In several LSDs, enzyme inhibitors have been used as small molecule chaperones to facilitate and increase the translocation of mutant protein from the endoplasmic reticulum to the lysosome. Enzyme activators with chaperone activity would be even more desirable as they would not inhibit the enzyme after translocation and might potentiate the activity of the enzyme that is successfully translocated. Herein we report our initial findings of a new series of acid alpha-glucosidase activators.

• Authors: Juan J Marugan, Wei Zheng, Omid Motabar, Noel Southall, Ehud Goldin, Ellen Sidransky, Ronald A Aungst, Ke Liu, Subir Kumar Sadhukhan, Christopher P Austin
• Journal: European journal of medicinal chemistry (Eur J Med Chem) Vol. 45 Issue 5 Pg. 1880-97 (May 2010) ISSN: 1768-3254 [Electronic] France
• PMID: 20206419 (Publication Type: Journal Article, Research Support, N.I.H., Intramural)

Chemical References

• Enzyme Activators
• Pyrimidinones
• alpha-Glucosidases

Topics

• Dose-Response Relationship, Drug
• Drug Evaluation, Preclinical
• Enzyme Activation (drug effects)
• Enzyme Activators (chemical synthesis, chemistry, pharmacology)
• Molecular Structure
• Pyrimidinones (chemical synthesis, chemistry, pharmacology)
• Stereoisomerism
• Structure-Activity Relationship
• alpha-Glucosidases (chemistry, metabolism)